Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
- Published In:
- Diabetes, obesity & metabolism, 26(2), 473-481 (2024)
- Authors:
- Patel, Hiren, Khunti, Kamlesh(3), Rodbard, Helena W, Bajaj, Harpreet S, Bray, Ross, Kindracki, Zbigniew, Rodríguez, Ángel
- Database ID:
- RPEP-09046
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-09046APA
Patel, Hiren; Khunti, Kamlesh; Rodbard, Helena W; Bajaj, Harpreet S; Bray, Ross; Kindracki, Zbigniew; Rodríguez, Ángel. (2024). Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.. Diabetes, obesity & metabolism, 26(2), 473-481. https://doi.org/10.1111/dom.15333
MLA
Patel, Hiren, et al. "Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.." Diabetes, 2024. https://doi.org/10.1111/dom.15333
RethinkPeptides
RethinkPeptides Research Database. "Gastrointestinal adverse events and weight reduction in peop..." RPEP-09046. Retrieved from https://rethinkpeptides.com/research/patel-2024-gastrointestinal-adverse-events-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.